Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 273

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer

Open access
Taieb, Julien, Le Malicot, Karine, Shi, Qian, Penault Lorca, Frédérique, Bouché, Olivier, Tabernero, Josep, Mini, Enrico, Goldberg, Richard M., Folprecht, Gunnar, Luc Van Laethem, Jean, Sargent, Daniel J., Alberts, Steven R., Francois Emile, Jean, Laurent Puig, Pierre, Sinicrope, Frank A.·2017·Journal of the National Cancer Institute

Abstract

Background: The prognostic value of BRAF and KRAS mutations within microsatellite-unstable (MSI) and microsatellite-stable (MSS) subgroups of resected colon carcinoma patients remains controversial. We examined this question in prospectively collected biospecimens from stage III colon cancer with separate analysis of MSI and MSS tumors from patients receiving adjuvant FOLFOX +/- cetuximab in two adjuvant therapy trials. Methods: Three groups were defined: BRAF Mutant, KRAS Mutant, and double wild-type. The analytic strategy involved estimation of study-specific effects, assessment of homogeneity of results, and then analysis of pooled data as no differences in patient outcome were found between treatment arms in both trials. Associations of mutations with patient outcome were analyzed, and multivariable models were adjusted for treatment and relevant factors. Results: Four thousand four hundred eleven tumors were evaluable for BRAF and KRAS mutations and mismatch repair status; 3934 were MSS and 477 were MSI. In MSS patients, all BRAF V600E mutations (hazard ratio [HR] = 1.54, 95% confidence interval [CI] = 1.23 to 1.92, P < .001), KRAS codon 12 alterations, and p.G13D mutations (HR = 1.60, 95% CI = 1.40 to 1.83, P < .001) were associated with shorter time to recurrence (TTR) and shorter survival after relapse (SAR; HR = 3.02 , 95% CI = 2.32 to 3.93, P < .001, and HR = 1.20, 95% CI = 1.01 to 1.44, P = .04, respectively). Overall survival (OS) in MSS patients was poorer for BRAF-mutant patients (HR = 2.01, 95% CI = 1.56 to 2.57, P < .001) and KRAS-mutant patients (HR = 1.62, 95% CI = 1.38 to 1.91, P < .001) vs wild-type. No prognostic role of KRAS or BRAF mutations was seen in MSI patients. Furthermore, no interaction was found between treatment arm (with or without cetuximab) and KRAS and BRAF mutations for TTR or OS in MSS patients. Conclusions: In a pooled analysis of resected stage III colon cancer patients receiving adjuvant FOLFOX, BRAF or KRAS mutations are independently associated with shorter TTR, SAR, and OS in patients with MSS, but not MSI, tumors. Future clinical trials in the adjuvant setting should consider these mutations as important stratification factors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jnci/djw272

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 273

Metadata

Authors
Taieb, J., Le Malicot, K., Shi, Q., Penault Lorca, F., Bouché, O., Tabernero, J., Mini, E., Goldberg, R. M., Folprecht, G., Luc Van Laethem, J., Sargent, D. J., Alberts, S. R., Francois Emile, J., Laurent Puig, P., & Sinicrope, F. A.
Venue
Journal of the National Cancer Institute
Published
2016-12-31
Volume
109
Issue
5
Pages
djw272
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
OpenAlex
W2561114892
Cited by
273
References
3
FWCI
9.58
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer. https://app.cochat.ai/papers/10.1093/jnci/djw272
The paper
Taieb, J., Le Malicot, K., Shi, Q., Penault Lorca, F., Bouché, O., Tabernero, J., Mini, E., Goldberg, R. M., Folprecht, G., Luc Van Laethem, J., Sargent, D. J., Alberts, S. R., Francois Emile, J., Laurent Puig, P., & Sinicrope, F. A. (2017). Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer. Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djw272

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.